SYHA-1813 | m-entrepreneurship.com

Product Name :
SYHA-1813

Search keywords :
SYHA1813

drugId :
null

Target Vo:
Vascular endothelial growth factor receptor

Target Vo Short Name :
VEGFR

Moa_Name:
Vascular endothelial growth factor receptor antagonists

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Shanghai Runshi Pharmaceutical Technology Co Ltd

Active Company_Name :
Shanghai Runshi Pharmaceutical Technology Co Ltd

Active Indication_Name:
Lung Neoplasms

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 1 Clinical

China Highest Status:
Phase 1 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Amlitelimab Protocol
COX2 Mouse mAb Data Sheet
RAB7 Antibody: RAB7 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 23 kDa, targeting to RAB7. It can be used for WB,ICC/IF,IHC-P,FC assays with tag free, in the background of Human, Mouse.

Author: Betaine hydrochloride

Related Posts